Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

NCT07417501 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Tongji Hospital